BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
For the purpose of this document, Interprofessional is defined as: Multiple health disciplines with diverse knowledge and skills who share an integrated set of goals and who utilize interdependent collaboration that involves communication, sharing of knowledge and coordination of services to provide... services to patients/clients and their care-giving systems. This best practice guideline, Developing and Sustaining Interprofessional Health Care: Optimizing patients/clients, organizational, and system outcomes is intended to foster healthy work environments. The focus in developing this guideline was identifying attributes of interprofessional care that will optimize quality outcomes for patients/clients, providers, teams, the organization and the system. This guideline identifies best practices to enable, enhance and sustain teamwork and interprofessional collaboration, and to enhance positive outcomes for patients/clients, systems and organizations. It is based on the best available evidence; where evidence was limited, the recommendations were based on the consensus of expert opinion.
more
3 March 2022
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an ...online platform, and is updated regularly as new evidence emerges.
more
Following flood levels of the hydrological stations monitored in Niamey (Niger Republic) and Malan Ville (Benin Republic) reaching the red alert zone, torrential rainfall and ensuing floods affected 91,254 people or 15,209 households in Jigawa, Kebbi, Kwara, Sokoto, and Zamfara state (amongst other ...states) of Nigeria on 6 October 2020. The flood incident was caused by the intensity of the rainfalls at the peak of the flood season and the release of dams located in neighbouring Niger, Cameroon, and Benin, which resulted in the Benue and Niger rivers overflowing and affecting communities living along their banks and in surrounding areas.
more
This quick guide offers basic information about COVID-19, the Sinovac-CoronaVac COVID-19 vaccine and what to
expect following vaccination: ...
Esta primeira versão de Medicamentos para prevenção da COVID-19: Orientação dinâmica da OMS aborda o uso de hidroxicloroquina para prevenção da COVID-19. Segue-se a publicação de uma análise sistemática e NMA que reuniu dados de seis estudos com 6.059 participantes que não tinham COVID-...19 e receberam hidroxicloroquina. Três estudos envolveram participantes que tiveram uma exposição conhecida a uma pessoa com infecção por SARS-CoV-2. Em resposta à divulgação dos dados de estudos, o GDG da OMS desenvolveu recomendações sobre a hidroxicloroquina, um agente anti-inflamatório que atua por meio do bloqueio dos receptores Toll-like, reduzindo a ativação das células dendríticas. É usada para tratar a artrite reumatoide e o lúpus eritematoso sistêmico. Tem um efeito antiviral contra muitos vírus in vitro, inclusive o SARS-CoV-2, mas não foi demonstrado um efeito antiviral clinicamente útil para nenhuma infecção viral.
more
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.
more
As pandemias virais costumam representar sérias ameaças ao equilíbrio dos sistemas de saúde, ao impor-lhes demandas extraor-dinárias e sustentadas, que podem ultrapassar a capacidade de atendimento, no que diz respeito tanto aos insumos e às tecnologias disponíveis, quanto aos recurs...os humanos/profissionais capacitados. Trazem o enorme desafio de equilibrar igualdade entre as pessoas e equidade na distribuição de riscos e benefícios entre elas.
Diante desse cenário de casos cada vez mais frequentes de COVID-19 na
população, surge a premente necessidade de se avaliarem as melhores práticas para a otimização da utilização dos meios e recursos disponíveis. Dessa forma, considerando o iminente risco de indisponibilidade de leitos de terapia intensiva e respiradores para todos os indivíduos, acometidos ou não pela doença, torna-se fundamental estabelecer critérios clínicos, técnicos e éticos, para a melhor utilização dos mesmos, para se conseguir otimizar resultado e gerar o maior benefício possível.
more
Esta orientação provisória foi desenvolvida com base na recomendação emitida pelo Grupo Consultivo Estratégico de Especialistas (SAGE) em imunização, em sua reunião extraordinária de 5 de janeiro de 2021, e atualizada durante sua reunião extraordinária de 27 de maio de 2021 (2), sendo no...vamente atualizada em 19 de novembro de 2021 e em 19 de janeiro de 2022. Foram coletadas as declarações de interesses de todos os colaboradores externos, sendo elas avaliadas quanto a quaisquer conflitos de interesse. Os resumos dos interesses relatados podem ser encontrados no site da reunião do SAGE e no site do Grupo de Trabalho do SAGE. A orientação se baseia em evidências resumidas no documento de referência sobre a vacina de mRNA BNT162b2 (Pfizer-BioNTech) contra COVID-19 (4), sendo novamente atualizado com base em novos dados provenientes de publicações científicas.
more
Uso de doxiciclina para prevenção e tratamento de pacientes com Covid-19
Orientações para a vigilância em saúde, no que se refere aos aspectos epidemiológicos e laboratoriais da vigilância genômica da covid-19
O Ministério da Saúde atualiza o Diagnosticar para Cuidar com o PLANO NACIONAL DE EXPANSÃO DA TESTAGEM PARA COVID-19 (PNE-Teste) que tem a finalidade de expandir o diagnóstico da covid-19 por meio do teste rápido de antígeno (TR-AG), para uso em indivíduos sintomáticos e assintomáticos, par...a monitorar a situação epidemiológica e direcionar os esforços desta Pasta ministerial na contenção da pandemia no território nacional.
more
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of a...cute COVID-19. It also includes advice on organising services for long COVID.
Updated 11 November 2021
more
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition...al dose of all WHO approved vaccines “since these individuals are less likely to respond adequately to vaccination following a standard primary vaccine series and are at high risk of severe COVID-19 disease.”
People aged 60 and older who received the Sinovac and Sinopharm vaccines should get a third dose too, the experts added, though use of other vaccines may also be considered depending on supply and access.
“When implementing this recommendation, countries should initially aim at maximizing 2-dose coverage in that population, and thereafter administer the third dose, starting in the oldest age groups”, they said.
SAGE has also reviewed a vaccine developed by Indian company Bharat Biotech and will issue a policy recommendation after WHO greenlights it for emergency use.
more
Временное руководство, Первый выпуск 8 января 2021 г., Обновлено 15 июня 2021 г., Обновлено 19 ноября 2021 г.